Acknowledgement
Supported by : 한국학술진흥재단
References
- Warner JO. The role of leukotriene receptor antagonists in the treatment of chronic asthma in childhood. Allergy 2001; 56 suppl 66:22-9
- Global Initiative for Asthma. Global strategy for asthma management and prevention. NIH publication no. 02-3659. Bethesda, MD : National Institutes of Health, 2002
- Salvi SS, Krishna MT, Sampson AP, Holgate ST. The anti-inflammatory effects of leukotriene-modifying drugs and their use in asthma. Chest 2001;119:1533-46 https://doi.org/10.1378/chest.119.5.1533
- Sanak M, Simon HU, Szczeklik A. Leukotriene C4 synthase promoter polymorphism and risk of aspirin-induced asthma. Lancet 1997;350:1599-600 https://doi.org/10.1016/S0140-6736(05)64015-9
- Asano K, Shiomi T, Hasegawa N, Nakamura H, Kudo H, Matsuzaki T, et al. Leukotriene C4 synthase gene A(-444) C polymorphism and clinical response to a CYS-LT1 antagonist, pranlukast, in Japanese patients with moderate asthma. Pharmacogenetics 2002;12:565-70 https://doi.org/10.1097/00008571-200210000-00009
- Currie GP, Lima JJ, Sylvester JE, Lee DK, Cockburn WJ, Lipworth BJ. Leukotriene C4 synthase polymorphisms and responsiveness to leukotriene antagonists in asthma. Br J Clin Pharmacol 2003;56:422-6 https://doi.org/10.1046/j.1365-2125.2003.01952.x
- Knorr B, Franchi LM, Bisgaard H, Vermeulen JH, LeSouef P, Santanello N, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics 2001;108:E48. Available from : URL : http://www.pediatrics.org/cgi/content/full/108/ 3/e48
- Santanello NC, Barber BL, Reiss TF, Friedman BS, Juniper EF, Zhang J. Measurement characteristics of two asthma symptom diary scales for use in clinical trials. Eur Respir J 1997;10:646-51
- Ducharme FM. Inhaled glucocorticoids versus leukotriene receptor antagonists as single agent asthma treatment : systematic review of current evidence. BMJ 2003;326:621-5 https://doi.org/10.1136/bmj.326.7390.621
- Bigby TD. The leukotriene C4 synthase gene and asthma. Am J Respir Cell Mol Biol 2000;23:273-6 https://doi.org/10.1165/ajrcmb.23.3.f197
- Tohda Y, Fujimura M, Taniguchi H, TakagiK, Igarashi T, Yasuhara H, et al. Leukotriene receptor antagonist, montelukast, can reduce the need for inhaled steroid while maintaining the clinical stability of asthmatic patients. Clin Exp Allergy 2002;32:1180-6 https://doi.org/10.1046/j.1365-2745.2002.01440.x
- Drazen JM, Yandava CN, Dube L, Szczerback N, Hippensteel R, Pillari A, et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet 1999;22:168-170. https://doi.org/10.1038/9680
- Fowler SJ, Hall IP, Wilson AM, Wheatley AP, Lipworth BJ. 5-Lipoxygenase polymorphism and in-vivo response to leukotriene receptor antagonists. Eur J Clin Pharmacol 2002;58:187-90 https://doi.org/10.1007/s00228-002-0458-1
- Sampson AP, Siddiqui S, Buchanan D, Howarth PH, Holgate ST, Holloway JW, et al. Variant LTC4 synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast. Thorax 2000;55(2 suppl):28S-31S
- Sambeek RV, Stevenson DD, Baldasaro M, Lam BK, Zhao J, Yoshida S, et al. 5' Flanking region polymorphism of the gene encoding leukotriene C4 synthase does not correlate with the aspirin-intolerant asthma phenotype in the United States. J Allergy Clin Immunol 2000;106:72-6 https://doi.org/10.1067/mai.2000.107603
- Sayers I, Barton S, Rorke S, Beghe B, Hayward B, Van Eerdewegh P, et al. Allelic association and functional studies of promoter polymorphism in the leukotriene C4 synthase gene(LTC4S) in asthma. Thorax 2003;58:417-24. https://doi.org/10.1136/thorax.58.5.417
- Mastalerz L, Nizankowska E, Sanak M, Mejza F, Pierzchalska M, Bazan-Socha S, et al. Clinical and genetic features underlying the response of patients with bronchial asthma to treatment with a leukotriene receptor antagonist. Eur J Clin Invest 2002;32:949-55 https://doi.org/10.1046/j.1365-2362.2002.01088.x